NCT06607991View on ClinicalTrials.gov

Blinatumomab for CNI-Resistant/Intolerant SRNS in Children

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

September 19, 2026

Study Completion Date

September 18, 2027

Conditions
CNI-resistant Steriod Resistant Nephrotic SyndromeCNI-intolerentSteriod Resistant Nephrotic SyndromeMultidrug Resistant Nephrotic Syndrome
Interventions
DRUG

Blinatumomab Treatment

Blinatumomab treatment for CNI-resistant/Intolerant pediatric steriod-resistant nephrotic syndrome Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.

Trial Locations (1)

310003

RECRUITING

Children's Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

The Children's Hospital of Zhejiang University School of Medicine

OTHER